Dr Reddy’s shares gain after Canada nod for semaglutide; marking first G7 approval

The Canadian semaglutide market is estimated to be over $1.5 billion, and analysts expect Dr. Reddy’s to benefit from a limited competition window of about six to nine months.

Leave a Reply

Your email address will not be published. Required fields are marked *